Form 4: Avenue Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Lindsay A. Rosenwald acquired 30,000 employee stock options in Avenue Therapeutics, Inc. on September 23, 2024.
Summary
- On September 23, 2024, Lindsay A. Rosenwald, a director of Avenue Therapeutics, Inc., acquired 30,000 employee stock options.
- The exercise price of these options is $2.46.
- The options vest in three equal installments on January 1, 2025, January 1, 2026, and January 1, 2027.
- The options expire on September 23, 2034.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of stock option grants. It doesn't inherently indicate positive or negative performance.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 09/23/2024 | Date of transaction: Lindsay A. Rosenwald acquired 30,000 employee stock options. |
| 01/01/2025 | One-third of the acquired stock options vest. |
| 01/01/2026 | One-third of the acquired stock options vest. |
| 01/01/2027 | One-third of the acquired stock options vest. |
| 09/23/2034 | Expiration date of the acquired stock options. |
| 09/25/2024 | Date of filing. |
Keywords
stock options, director, Avenue Therapeutics, ATXI, insider trading, Form 4, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.